tbuckley/cabot-search huggingface dataset:
Correction: Nelson Textbook of Pediatrics, 17th Edition
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Total Pancreatectomy for Fulminant Pancreatitis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE ETIOLOGY OF CANCER.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRANCE
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bilateral carotid artery occlusion in a young adult. Clinicopathological report of a case associated with oral contraceptives
Authors: M. M. Mandel
Journal: JAMA (1969)

Complete bilateral carotid artery occlusion in a young adult is unusual and, to our knowledge, it has not been previously reported. The patient had been receiving oral progestational agents for nine months prior to the onset of occlusion which produced clinical manifestations of a decerebrate state. Bilateral carotid angiography demonstrated bilateral carotid artery occlusion. At autopsy, arteriosclerotic plaques were found in the completely occluded carotid vessels. Hypercoagulability of the blood associated with the use of oral contraceptives and the arteriosclerotic plaques were probably the etiologic factors in producing the occlusion.
Authors’ Response
Authors: María‐Victoria Mateos, Hongliang Shi, Jesús F. San Miguel
Journal: American Journal of Hematology (2015)

On behalf of our co-authors, we are pleased to respond to the comment from Hsieh et al., 1 on our manuscript “Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study” 2. While noting that our study provides new evidence that an increased cumulative bortezomib dose may prolong overall survival in newly diagnosed transplant-ineligible patients with multiple myeloma, Hsieh et al. comment on the potential “immortal time bias” inherent to this type of retrospective analysis. Such limitations of retrospective analyses are acknowledged in our manuscript, and the 180-day and 90-day landmark analyses were performed to attempt to overcome, at least in part, such a potential bias. In these landmark analyses, only subjects who were alive at the landmark time point were included in the analysis. Hence, by excluding subjects who died prior to these time points (and therefore received fewer bortezomib doses), the results provide a fair comparison of survival according to the cumulative bortezomib dose received. Although a Cox regression analysis using the cumulative bortezomib dose as a time-dependent covariate, as suggested by Hsieh et al., would be an alternative way of performing such an analysis, it would be harder to interpret the results in a clinically meaningful way; one could only say there was a strong association between cumulative dose and survival. While acknowledging the different data analysis approaches, the limitations of the post hoc nature of these analyses, and that the optimum cumulative dose may vary among patient subgroups, we believe the approach taken in our study provided the most quantifiable results of most relevance to the myeloma community. Hsieh et al. also suggest that a randomized controlled trial would be the ideal way to determine whether an increased cumulative bortezomib dose is associated with prolonged overall survival. While we agree with this statement, the volume of evidence 3-8 suggesting that higher cumulative dose is associated with improved outcomes in patients with multiple myeloma makes it difficult to conduct a bortezomib clinical trial to test this hypothesis. Therefore, we believe that the best alternative is the approach taken in our study, namely a retrospective analysis embedded in a large, randomized, controlled phase 3 trial. María-Victoria Mateos1*, Hongliang Shi2, Jesús F. San Miguel3 1Hospital Universitario Salamanca, Instituto Biosanitario De Salamanca (IBSAL), Spain; 2Takeda Pharmaceuticals International Co., Cambridge, Massachusetts; 3Centro Investigación Medica Aplicada, Clinica Universidad De Navarra, Pamplona, Spain
Contraception
Authors: Nathan Kase
Journal: JAMA (1974)

As a volume in the series "Benchmark Papers,"<i>Contraception</i>should meet two objectives: (1) by expert selection and careful editorial organization and annotation, it should bring together key papers in the field, and (2) provide an overview of<i>homo sapiens</i>struggling for enlightenment as he takes his sometimes very halting steps toward independence... that can only come through knowledge.... [S]uch knowledge has the very practical result that men and women can now, easily and successfully, separate sexual intercourse from reproduction.... In terms of these expectations, the editor of this volume has fallen somewhat short of the mark in the first, and has succeeded reasonably well in the second. In each of 12 sections,<i>Contraception</i>traces the evolution of contraceptive methods from biblical references on coitus interruptus to the unrealized promise of the prostaglandins, from observations on the destructive operations performed by the Aborigines to the contrasting
HOW SUPERSTITIONS ARE REINFORCED.
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Wordings
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diuretic Agents
Authors: John B. Sharefkin
Journal: JAMA (1974)

Mesenteric infarction in the absence of organic vascular occlusion represents the most common and lethal variety of intestinal ischemia. Hemorrhagic shock, decreases in splanchnic perfusion of cardiac origin, and digitalis glycosides have been implicated in the pathogenesis of this entity, but no single causative factor can be identified in a significant number of individuals. Three patients are described in whom massive extracellular volume deficits induced by diuretic therapy initiated the development of nonocclusive mesenteric ischemia. Drastic diuresis should be monitored meticulously in patients with cardiac disease, especially in those taking digitalis or its derivatives. (<i>JAMA</i>229:1451-1453, 1974)
Studies on the bacteremia of bacterial endocarditis
Authors: A. S. Werner
Journal: JAMA (1967)

In 206 cases of bacterial endocarditis with positive blood cultures, 95% of 789 blood cultures were positive for the causative microorganisms. In streptococcal endocarditis, the first blood culture was positive in 96% of the cases, and one of the first two blood cultures was positive in 98% of the cases. In endocarditis caused by microorganisms other than streptococci, the first blood culture was positive in 82% of the cases, and one of the first two blood cultures was positive in all of the cases. The incidence of positive cultures was slightly reduced in those cases in which the patient had received an antimicrobial agent within two weeks prior to blood culture. The bacteremia in the 206 cases of bacterial endocarditis was persistent and of low magnitude.
Spinal Anesthesia: Technic and Clinical Application
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Meeting
Authors: Henry Cohen, Dr Bradley Gave
Journal: Annals of the Rheumatic Diseases (1951)

RHEUMATIC DISEASES infection), in dermatomyositis, and in scieroderma.In cases of rheumatoid arthritis treated with ACTH or cortisone, C-reactive protein rapidly disappeared.It was suggested that the test might be profitably used in assessing the response to other therapeutic agents with possible anti-rheumatic activity.Radiotherapy in Ankylosing Spondylitis, by Dr. J. L. Potter.An investigation of the clinical, haematological, and biochemical effects of radiotherapy in ten cases of ankylosing spondylitis and one case of spinal osteo-arthritis were described, and the results reported.It was suggested that the early clinical improvement observed may be mediated partly by an increased adreno-cortical activity, and further experiments to confirm this hypothesis were discussed.The Sterno-Manubrial Joint in Rheumatoid Arthritis and Ankylosing Spondylitis, by Dr.Bruce Cruickshank.The histological changes which occur in the manubrio-sternal joint and in symphysis pubis in ankylosing spondylitis were discussed, illustrated, and correlated with the radio- logical appearances.It was suggested that the pathological process in these cartilaginous joints is analogous to that seen in synovial joints in the disease.Clinical and Metabolic Effects of Glutathione in Rheumatoid Arthritis, by Dr. A. P.Meiklejohn.The clinical effect obtained by the intravenous administration of glutathione to a case of rheumatoid arthritis was described, but it was reported that attempts to repeat this effect had met with failure.The theoretical implications were discussed with special reference to the utilization of vitamin C in rheumatoid arthritis.A Method of Demonstrating the Union of Antibody and Antigen in Tissues, by Dr. Alan G. S. Hill.The use of fluorescein-tagged antibody as a specific cytochemical reagent for the detection of antigenic material in tissues was described.Illustrations were shown of results obtained in a study of the localization of an injected bacterial polysaccharide in animal tissues.The possibility of applying the method to a study of the rheumatic diseases was discussed.
Entecavir Surprise
Authors: Martin S. Hirsch
Journal: New England Journal of Medicine (2007)

The truly remarkable advances in the treatment of human immunodeficiency virus type 1 (HIV-1) infection have turned a once nearly uniform death sentence into a treatable condition. The survival benefits resulting from the use of antiretroviral drugs are estimated to have saved 3 million years of life; these benefits compare favorably with those of many other interventions for chronic diseases.1 In the 20 years since zidovudine was first approved, more than 20 other antiretroviral drugs have emerged, including inhibitors of HIV-1 reverse transcriptase, protease, and attachment and entry. Several other experimental agents now in expanded-access programs may be approved in . . .
Citations
Authors: Albert D. Lasker, Michael E. DeBakey
Journal: JAMA (1974)

<h3>John Charnley, DSc, FRCS</h3> Professor Charnley receives the Albert Lasker Clinical Medical Research Award for his original, innovative concepts for total prosthetic joint replacement, developed during the 1950s, which have had a major impact on improving the treatment and rehabilitation of patients with crippling joint diseases—especially arthritis. Combining his talents as an orthopedic surgeon and biomedical engineer, Professor Charnley conducted original laboratory and clinical research in joint lubrication and the biomedical characteristics of joint opposition. The investigations led to the development of a revolutionary design of a total hip joint replacement and the introduction of the use of methyl methacrylate as a plastic cement to firmly affix the prosthetic components to the bone. Although the pioneering work on joint prosthetics going back to 1908 cannot be ignored, the present advances were made possible by Professor Charnley's unique concepts. The techniques and concepts that he introduced in 1961 have given patients
Abstract 4374: Identification and characterization of active components of antrodia camphorata mycelia on targeting cancer initiating cell
Authors: Ching-Wen Chang, Jeng-Fan Lo
Journal: Cancer Research (2011)

Abstract Background: Cancer initiating cells (CICs) represent a rare subpopulation of cancer cells, which are responsible for tumor growth. Cancer initiating cells such as oral cancer-cancer initiating cells (OC-CICs), are often resistant to either radiotherapy or chemotherapy. Therefore, screening and development for drug candidates that target OC-CICs specifically will benefit for future oral cancer therapy. Methods: First, we used the in vitro cell-based ALDH activity assay system, which has been demonstrated as a CICs marker, to screen for the active components from purified compounds of Antrodia Camphorata Mycelia extract (ACME), which can target OC-CICs. The growth inhibition and cell differentiation ability of OC-CICs treated with purified compounds from ACME were evaluated. In addition, the self-renewal ability and stemness properties of ACMEs treated OC-CICs were examined. Furthermore, xenotransplantation assay was applied to test the tumorigenicity of OC-CICs treated with isolated ACMEs. Finally, we investigated the molecular mechanisms mediated by ACME treatment on OC-CICs. Results: Herein, we first found out that an ACME's purified components, CH-190-WS-D, significantly downregulated the ALDH activity of oral cancer cells. Treatment of CH-190-WS-D significantly induced cell death and enhanced the differentiation capability of OC-CICs but not the major population of oral cancer cells. Moreover, we found that treatment of CH-190-WS-D reduced the self-renewal ability and stemness properties of OC-CICs. The in vitro tumorigenic properties, including cell migration and anchorage independent growth of OC-CICs, were lessened by CH-190-WS-D treatment. Furthermore, treatment of CH-190-WS-D suppressed tumor growth of nude mice bearing xenografts. Finally, treatment of CH-190-WS-D results in down-regulation of PI3K/AKT/mTOR molecular mechanisms which play important roles in CICs. Conclusion: Our studies reveal the ACME's purified components can reduce stemness properties and tumorigenicity of OC-CICs. Eventually, we can discover drug candidates from ACME's purified components for alternative oral cancer therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4374. doi:10.1158/1538-7445.AM2011-4374
Does fludarabine have a beneficial effect in recessive dystrophic epidermolysis bullosa?
Journal: British Journal of Dermatology (2021)

Linked Article: Vanden Oever et al. Br J Dermatol 2021; 185:380-390. Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic disorder. Patients with RDEB experience severe painful blistering and skin fragility due to separation of two layers of the skin: the dermis and epidermis. This occurs because type VII collagen (C7) is deficient or absent in the skin. C7 is a major component responsible for tethering the epidermis to the dermis. The skin heals with disfiguring scarring, and patients are at risk of secondary infection and an aggressive form of squamous carcinoma, a type of skin cancer. There is currently no cure but there are encouraging results from some experimental treatments. One treatment is haematopoietic stem cell transplantion, where the engrafted cells appear to increase the amount of C7 (a process called deposition) over the long-term. Unfortunately, this treatment requires long term immunosuppression and this is particularly risky in patients with RDEB, who are prone to infections. The authors, based in Minneapolis, USA, explored whether any of the drugs used in chemotherapy treatment used before transplant might have an effect on C7 deposition. They found that fludarabine influences the production of C7 in affected cells in RDEB. They describe various mechanisms for this effect. They stress the need to determine how much the increased C7 deposition following haematopoietic stem cell transplantation is because of the engrafted cells, and how much is from the patient's own cells stimulated by drugs such as fludarabine. They caution that drugs may cause deposition of non-functional C7, which could be harmful. Unfortunately, fludarabine is generally too toxic to use in patients with RDEB, but there is the possibility of less toxic analogues that could have the same desirable effect on C7 deposition and have clinical benefit.